Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
Public ClinicalTrials.gov record NCT01844505. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to show that Nivolumab and/or Nivolumab in combination with Ipilimumab will extend progression free survival and overall survival compared to Ipilimumab alone.
Study identification
- NCT ID
- NCT01844505
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 945 participants
Conditions and interventions
Conditions
Interventions
- Nivolumab Biological
- Ipilimumab Biological
- Placebo for Nivolumab Biological
- Placebo for Ipilimumab Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 11, 2013 (Actual)
- Primary completion
- Aug 1, 2016 (Actual)
- Completion
- Apr 19, 2024 (Actual)
- Last update posted
- May 21, 2025
2013 – 2024
United States locations
- U.S. sites
- 46
- U.S. states
- 27
- U.S. cities
- 38
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0085 | Gilbert | Arizona | 85234 | — |
| University of Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| Local Institution - 0046 | La Jolla | California | 92093-0698 | — |
| Local Institution - 0053 | Los Angeles | California | 90025 | — |
| Local Institution - 0014 | Los Angeles | California | 90095 | — |
| Comprehensive Cancer Center At Desert Regional Medical Ctr | Palm Springs | California | 92262 | — |
| Local Institution - 0066 | Rancho Mirage | California | 92270 | — |
| California Pacific Medical Center Research Institute | San Francisco | California | 94115 | — |
| Local Institution - 0049 | San Francisco | California | 94143 | — |
| Local Institution - 0052 | Aurora | Colorado | 80045 | — |
| Local Institution - 0084 | New Haven | Connecticut | 06520 | — |
| Local Institution - 0098 | Washington D.C. | District of Columbia | 20007 | — |
| Local Institution - 0183 | Washington D.C. | District of Columbia | 20010 | — |
| Local Institution - 0042 | Jacksonville | Florida | 32207 | — |
| Local Institution - 0008 | Orlando | Florida | 32806 | — |
| Local Institution - 0051 | Atlanta | Georgia | 30322 | — |
| Maine Center For Cancer Medicine | Scarborough | Maine | 04074 | — |
| Local Institution - 0080 | Lutherville | Maryland | 21093 | — |
| Local Institution - 0081 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0082 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0083 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0087 | Ann Arbor | Michigan | 48109 | — |
| Local Institution - 0187 | Minneapolis | Minnesota | 55407 | — |
| Local Institution - 0065 | Jackson | Mississippi | 39216 | — |
| Local Institution - 0067 | St Louis | Missouri | 63110 | — |
| Local Institution - 0015 | Las Vegas | Nevada | 89148 | — |
| Local Institution - 0188 | Morristown | New Jersey | 07962 | — |
| Local Institution - 0068 | Albuquerque | New Mexico | 87106 | — |
| Local Institution - 0079 | Albany | New York | 12206 | — |
| Local Institution - 0174 | New York | New York | 10016 | — |
| Local Institution - 0070 | New York | New York | 10020 | — |
| Local Institution - 0047 | Charlotte | North Carolina | 28204 | — |
| Local Institution - 0048 | Durham | North Carolina | 27710 | — |
| Local Institution - 0007 | Cleveland | Ohio | 44106 | — |
| Local Institution - 0045 | Portland | Oregon | 97213 | — |
| Local Institution - 0061 | Allentown | Pennsylvania | 18102 | — |
| Local Institution - 0112 | Bethlehem | Pennsylvania | 18015 | — |
| Local Institution - 0069 | Pittsburgh | Pennsylvania | 15232 | — |
| Local Institution - 0154 | Greenville | South Carolina | 29605 | — |
| Local Institution - 0062 | Nashville | Tennessee | 37203 | — |
| Local Institution - 0064 | Nashville | Tennessee | 37232 | — |
| Local Institution - 0044 | Dallas | Texas | 75246 | — |
| Texas Oncology | Dallas | Texas | 75246 | — |
| Local Institution - 0088 | Houston | Texas | 77210 | — |
| Local Institution - 0089 | Salt Lake City | Utah | 84112 | — |
| Local Institution - 0054 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 104 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01844505, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 21, 2025 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01844505 live on ClinicalTrials.gov.